Oflar, ErsanKoyuncu, AtillaAlp, Murat ErdemKaraosmanogul, Hayat KumbasarUnal, OrcunBeyaz, Metin OnurOztas, Didem Melis2024-09-182024-09-1820220010-86501803-7712https://doi.org/10.33678/cor.2021.123https://hdl.handle.net/20.500.12483/7688Background: The first reports on coronaviruse disease 2019 (COVID-19) revealed an exaggerated mortality rate in hypertensive patients. In this regard, concerns about angiotensin-converting enzyme (ACE) inhibitors' and angiotensin-receptor blockers' (ARBs) have been aroused. Our aim in this study was to evaluate the potential bad outcome effect of hypertension and anti-hypertensive therapy on COVID-19. Methods: 183 patients with polymerase-chain-reaction (PCR)-proven COVID-19, who were admitted to our hospital and consulted to cardiology department between 15th of March and 15th of April 2020 were inclu-ded. Data were recruited from hospital records. Results: Thirty-two out of 183 patients with COVID-19 died in hospital. Hypertension incidence was not sta-tistically different between patients who survived and died (76 [50.3%] vs 19 [59.4%, p = 0.352]). Although the usage rate of ACEI were similar among groups, ARB usage rate was significantly higher in patients who died than survived (11 [34.4%] vs 23 [15.2%], p = 0.011). Binary regression analysis showed an association between ARBs and mortality (OR: 0.032, 95% CI 1.045-2.623, p = 0.032). Conclusion: Our study confirmed previous concerns regarding a potential harmful effects of ARBs on COVID-19 related mortality.eninfo:eu-repo/semantics/openAccessAngiotensin converting enzymeCOVID-19PandemicsRenin-angiotensinThe Effect of Renin-Angiotensin Blockers on COVID-19 Related Mortality: A Tertiary Center's ExperienceArticle64327728110.33678/cor.2021.1232-s2.0-85135095200Q4WOS:000826775300003N/A